de Rosbo N K, Ben-Nun A
Dept. of Immunology, The Weizmann Institute of Science, Rehovot, 76100, Israel.
J Autoimmun. 1998 Aug;11(4):287-99. doi: 10.1006/jaut.1998.0202.
Until recently, the search for the 'culprit' autoantigen towards which deleterious autoimmunity is directed in multiple sclerosis (MS) centered mostly on myelin basic protein (MBP) and proteolipid (PLP), the two most abundant protein components of central nervous system (CNS) myelin, the target tissue for the autoimmune attack in MS. Although such research has yielded important data, furthering our understanding of the disease and opening avenues for possible immune-specific therapeutic approaches, attempts to unequivocally associate MS with MBP or PLP as primary target antigens in the disease have not been successful. This has led in recent years to a new perspective in MS research, whereby different CNS antigens are being investigated for their possible role in the initiation or progression of MS. Interesting studies in laboratory animals show that T-cells directed against certain non-myelin-specific CNS antigens are able to cause inflammation of the CNS, albeit without expression of clinical disease. However, reactivity to these antigens by MS T-cells has not been demonstrated. Conversely, reactivity by MS T-cells to non-myelin-specific antigens such as heat shock proteins, could be observed, but the pathogenic potential of such reactivity has not been corroborated with the encephalitogenicity of the antigen. More relevant to MS pathogenesis may be, as we outlined in this review, the autoimmune reactivity directed against minor myelin proteins, in particular the CNS-specific myelin oligodendrocyte glycoprotein (MOG). Here, we review the current knowledge gathered on T-cell reactivity to possible target antigens in MS in the context of their encephalitogenic potential, and underline the facets which make MOG a highly relevant contender as primary target antigen in MS, albeit not necessarily the only one.
直到最近,在多发性硬化症(MS)中,针对有害自身免疫所指向的“罪魁祸首”自身抗原的研究主要集中在髓鞘碱性蛋白(MBP)和蛋白脂质(PLP)上,这两种是中枢神经系统(CNS)髓鞘中含量最丰富的蛋白质成分,而髓鞘正是MS自身免疫攻击的靶组织。尽管此类研究已产生重要数据,增进了我们对该疾病的理解并为可能的免疫特异性治疗方法开辟了道路,但试图明确将MS与MBP或PLP作为该疾病的主要靶抗原联系起来的尝试并未成功。这在近年来导致了MS研究的一个新视角,即正在研究不同的中枢神经系统抗原在MS发病或进展中的可能作用。对实验动物的有趣研究表明,针对某些非髓鞘特异性中枢神经系统抗原的T细胞能够引起中枢神经系统炎症,尽管没有临床疾病表现。然而,尚未证实MS的T细胞对这些抗原具有反应性。相反,可以观察到MS的T细胞对非髓鞘特异性抗原如热休克蛋白的反应性,但这种反应性的致病潜力尚未通过抗原的致脑炎性得到证实。正如我们在本综述中所概述的,与MS发病机制更相关的可能是针对次要髓鞘蛋白的自身免疫反应性,特别是中枢神经系统特异性的髓鞘少突胶质细胞糖蛋白(MOG)。在此,我们在其致脑炎性潜力的背景下综述了目前关于MS中T细胞对可能的靶抗原反应性的知识,并强调了使MOG成为MS主要靶抗原的高度相关竞争者的方面,尽管不一定是唯一的一个。